Ruhi Dixit

Dr. Ruhi Dixit

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JPJyotsnaa Pillai
Jyotsnaa Pillai
TCTanvi Chincholkar
Tanvi Chincholkar
Ruhi DixitRuhi Dixit
Ruhi Dixit
Manoj PandeyManoj Pandey
Manoj Pandey
Background: Head and neck squamous cell cancer (HNSCC) is the most common cancer associated with chewing tobacco, in the world. As this is divided in to sites and subsites, it does not make it to top 10 cancers. The most common subsite is the oral cancer. At the time of diagnosis, more than 50% of patients with oral squamous cell cancers (OSCC) had advanced disease, indicating the lack of availability of early detection and risk assessment biomarkers. The new protein biomarker development and discovery will aid in early diagnosis and treatment which lead to targeted treatment and ultimately a good prognosis. Methods: This systematic review was performed as per PRISMA guidelines. All relevant studies assessing characteristics of oral cancer and proteomics were considered for analysis. Only human studies published in English were included, and abstracts, incomplete articles, and cell line or animal studies were excluded. Results: A total of 308 articles were found, of which 112 were found to be relevant after exclusion. The present review focuses on techniques of cancer proteomics and discovery of biomarkers using these techniques. The signature of protein expression may be used to predict drug response and clinical course of disease and could be used to individualize therapy with such knowledge. Conclusions: Prospective use of these markers in the clinical setting will enable early detection, prediction of response to treatment, improvement in treatment selection, and early detection of tumor recurrence for disease monitoring. However, most of these markers for OSCC are yet to be validated.

5 January 2017 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
Ruhi DixitRuhi Dixit
Ruhi Dixit
Manoj PandeyManoj Pandey
Manoj Pandey
STSunil Kumar Tripathi
Sunil Kumar Tripathi
ADAmit Nandan Dwivedi
Amit Nandan Dwivedi
VSVijay Kumar Shukla
Vijay Kumar Shukla

31 January 2018 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
Manoj PandeyManoj Pandey
Manoj Pandey
KKKrishna Kiran Kannepali
Krishna Kiran Kannepali
Ruhi DixitRuhi Dixit
Ruhi Dixit
MKMohan Kumar
Mohan Kumar
Head and neck cancers are the commonest cancer in Southeast Asia. Despite being a surface cancer, it is associated with significant morbidity as despite early detection by the patients they often report for treatment late and hence are associated with poor prognosis. The role of neoadjuvant chemotherapy in head and neck cancer is still under evaluation; there is a large subgroup of population that does not respond to chemotherapy, and hence, most studies have failed to show any survival benefit. This study evaluated the role of neoadjuvant therapy with docetaxel and carboplatin in patients with oral cancer and correlated the response to human papilloma virus, EGFR1, EGFR2, and GADD45 expression. A total of 24 locally advanced, non-metastatic oral cancer patients were included in the study. Tumor biopsies were taken prior to the start of neoadjuvant therapy for expression of EGFR, Her-2-Neu, and GADD45 by immunohistochemistry and for HPV by PCR. The response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria after three cycles of chemotherapy. Statistical analysis was performed using correlation and Kaplan–Meier analysis; the difference in survival was calculated with log rank test. A total of 21 male and 3 female with a mean age of 53.12 years were enrolled. Sixty-five percent of these received three cycles of chemotherapy. Five patients were positive for HPV 16 and none for HPV 18. Twenty-two of 24 patients showed GADD45 expression, 3 showed expression of Her-2-Neu while all 24 showed expression for EGFR1 protein. Two-year overall survival was 81%; GADD45 expressions were found to significantly affect the overall and disease-free survival, while any of the other protein expression studied and HPV status was not significant. The result of the present study shows significant downgrading of the oral cancers with neoadjuvant chemotherapy suggesting its utility in borderline operable cases. However, the response of chemotherapy does not appear to be related to the expression of EGFR, Her-2-Neu, and GADD45 protein or presence of HPV. Bone involvement, perineural invasion, and GADD45 expression significantly predict OS and DFS. All patients who did not express Gadd45 died before 2 years. Study with more subjects and longer follow-up should be carried out to elucidate this relation further.

23 November 2012 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
Ruhi DixitRuhi Dixit
Ruhi Dixit
PSPiyush Srivastava
Piyush Srivastava
SBSomprakas Basu
Somprakas Basu
PSPradeep Srivastava
Pradeep Srivastava
PMPradeep Kumar Mishra
Pradeep Kumar Mishra
VSVijay Kumar Shukla
Vijay Kumar Shukla

19 December 2015 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
Ruhi DixitRuhi Dixit
Ruhi Dixit
GSGyanendra Singh
Gyanendra Singh
Manoj PandeyManoj Pandey
Manoj Pandey
SBSomprakas Basu
Somprakas Basu
SBSatyanam Kumar Bhartiya
Satyanam Kumar Bhartiya
VSVijay Kumar Shukla
Vijay Kumar Shukla

5 June 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
DDDoutrina Das
Doutrina Das
Ruhi DixitRuhi Dixit
Ruhi Dixit
Manoj PandeyManoj Pandey
Manoj Pandey